Orthopedic technology company Enovis announced that it will acquire French company eCential Robotics for €155 million upfront, or approximately $180 million, in a deal aimed at making surgical robotics a major focus of the company’s strategy. Enovis plans to begin rolling out a robot for knee surgery in late 2028, followed by a robot for shoulder surgery during 2029.
Enovis currently operates in two main segments: surgically implanted bone and joint repair devices, and rehabilitation, pain management, and physical therapy products. The acquisition comes as competitors such as Johnson & Johnson and Stryker have expanded their presence in surgical robotics for orthopedic procedures, making the area a clear competitive gap for Enovis.
From Partnership to Owning the Technology
Enovis was already working with eCential, but the deal will bring robotic capabilities inside the company instead of relying on an external partnership. CEO Damien McDonald said that owning these capabilities internally would give Enovis greater speed and flexibility in responding to how physicians interact with the development of the next generation of technologies.
eCential has experience developing robotic systems, including the Velys Spine system that it developed for Johnson & Johnson. BTIG believes this experience could reduce market-acceptance risks for future products, although it does not guarantee the success of the new devices or their regulatory and clinical adoption.
Product Roadmap and Technical Differentiation
The deal will enable Enovis to add robotic capabilities to the Astra ecosystem, which currently includes augmented-reality glasses and software for procedure planning. The company did not disclose all specifications for the knee robot, but said the device would include features and subtle distinctions that set it apart from competing systems.
In shoulder surgery, Enovis management believes there is greater room for differentiation because current options include Smith & Nephew’s Cori, Stryker’s Mako, and Zimmer Biomet’s Rosa. McDonald said current robotic designs in this area remain less than ideal, noting that a robotic arm with seven degrees of freedom would be among the distinguishing elements of the system the company is developing with eCential.
What Changes in Practice?
The deal combines a software platform and existing assistive technologies at Enovis with eCential’s expertise in robotics engineering, software, and hardware. The French company employs approximately 50 people in France, working in engineering, software, and hardware development, along with small quality, regulatory, and manufacturing teams. Enovis said the manufacturing and assembly teams can produce between 75 and 100 robots annually.
For hospitals and surgeons, the announcement does not mean that new devices will be available in the near term; the targeted knee robot is still not expected until late 2028, while the shoulder system is due in 2029. The source also did not provide details on pricing, initial markets, or the regulatory stages required before launch.
Deal Cost and Open Questions
In addition to the upfront payment, Enovis committed to paying up to €35 million more, tied to development milestones for the knee and shoulder robots. The company expects the deal to pressure its margins during 2027, a point criticized by BTIG analysts, although they said the company’s current valuation does not fully reflect the progress it has made on this path.
Enovis shares fell 16.5% to close at $20.53 on Tuesday, according to the source material. This indicates that investors are weighing the opportunity to build an in-house surgical robotics business against the investment cost and the long period before the products reach the market. Enovis’s ability to turn eCential’s expertise into approved and scalable devices, particularly for shoulder surgery, remains the decisive factor in assessing the deal’s impact.